Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 1, January, p. 25–33

doi: 10.17219/acem/76858

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Progesterone decreases the extent of ovarian damage caused by cisplatin in an experimental rat model

Saim Ozdamar1,E,F, Mine Islimye Taskin2,A,F, Gozde Ozge Onder1,B, Emin Kaymak1,B, Munevver Baran3,C, Arzu Yay1,A,B,C,D,E,F

1 Department of Histology and Embryology, Medicine Faculty, Erciyes University, Kayseri, Turkey

2 Department of Obstetrics and Gynecology, Medicine Faculty, University of Balikesir, Turkey

3 Department of Pharmaceutical Basic Science, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey

Abstract

Background. Apart from the role of progesterone in reproductive physiology, the protective role of exogenously administered progesterone was observed in various injuries, such as neurologic defects and acute kidney injury.
Objectives. The aim of the present study was to investigate the effects of progesterone therapy on the immunoexpression of anti-Müllerian hormone (AMH) and the number of apoptotic cells in ovarian damage induced with cisplatin, a chemotherapeutic agent, in an experimental rat model.
Material and Methods. Forty rats were randomly divided into 4 groups; the control group (the saline group), the cisplatin-treated group (rats were injected with 5 mg/kg/week cisplatin intraperitoneally (i.p.)), the cisplatin + progesterone-treated group (the rats were pretreated with 8 mg/kg progesterone intramuscularly (i.m.) (8 mg/kg) before they were injected with 5 mg/kg/week cisplatin i.p.), and the progesteronetreated group (the rats were treated with 8 mg/kg progesterone i.m.). The ovaries were removed from the rats in all groups 5 days after the final injection of cisplatin.
Results. Histopathologic examination and follicle counting were performed. The immunoreactivity intensity of AMH and apoptosis were compared. Histological analysis of the ovaries treated with cisplatin showed ovarian damage. Immunohistochemical analysis showed that the immunoreactivity intensity of AMH, a biomarker that discriminates the degree of ovarian damage, was lower in the cisplatin-treated groups than in other groups. Terminal deoxynucleotide transferase-mediated 20-deoxyuridine 50-triphosphate nick endlabeling (TUNEL) assays showed that the increase in the number of apoptotic cells was statistically significant in the cisplatin-treated group compared to the control group (p < 0.05). Progesterone administration with cisplatin resulted in decreases in TUNEL-positive cells. The decrease in the number of apoptotic cells was statistically significant in the cisplatin + progesterone-treated group compared to the control group (p < 0.001).
Conclusion. Our results showed that using progesterone as an adjuvant agent against ovarian damage in patients undergoing cancer chemotherapy with cisplatin is beneficial.

Key words

apoptosis, cisplatin, anti-Müllerian hormone, ovarian damage, progesterone

References (30)

  1. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307–320.
  2. Taskin MI, Yay A, Adali E, Balcioglu E, Inceboz U. Protective effects of sildenafil citrate administration on cisplatin-induced ovarian damage in rats. Gynecol Endocrinol. 2015;31(4):272–277.
  3. Yeh J, Kim BS, Liang YJ, Peresie J. Gonadotropin stimulation as a challenge to calibrate cisplatin induced ovarian damage in the female rat. Reprod Toxicol. 2009;28:556–562.
  4. Yazici A, Sari ES, Yay A, et al. The protective effect of selenium in cisplatin-related retinotoxicity. Cutan Ocul Toxicol. 2014;33(4):327–332.
  5. De Castilhos J, Hermel EE, Rasia-Filho AA, Achaval M. Influence of substitutive ovarian steroids in the nuclear and cell body volumes of neurons in the posterodorsal medial amygdala of adult ovariectomized female rats. Neurosci Lett. 2010;469(1):19–23.
  6. Cheng J, Zhang J, Ma X, Su D. Frequency-dependent acceleration of cardiac repolarization by progesterone underlying its cardiac protection against drug-induced proarrhythmic effects in female rabbits. Eur J Pharmacol. 2012;689(1–3):172–178.
  7. Ghasemi M, Nematbakhsh M, Pezeshki Z, Soltani N, Moeini M, Talebi A. Nephroprotective effect of estrogen and progester-one combination on cisplatin-induced nephrotoxicity in ovariectomized female rats. Indian J Nephrol. 2016;26(3):167–175.
  8. Sandhi J, Singh JP, Kaur T, Ghuman SS, Singh AP. Involvement of progesterone receptors in ascorbic acid-mediated protec-tion against ischemia-reperfusion-induced acute kidney injury. J Surg Res. 2014;187(1):278–288.
  9. Themmen AP. Anti-Müllerian hormone: Its role in follicular growth initiation and survival and as an ovarian reserve marker. J Natl Cancer Inst Monogr. 2005;34:18–21.
  10. Yeh J, Kim BS, Peresie J, Liang YJ, Arroyo A. Serum and ovarian Müllerian inhibiting substance, and their decline in reproductive aging. Fertil Steril. 2007;87(5):1227–1230.
  11. Lee SJ, Schover LR, Partridge AH, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology rec-ommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917–2931.
  12. Li X, Kang X, Deng Q, Cai J, Wang Z. Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: A controlled experimental animal study. Re-prod Biol Endocrinol. 2013;11:16. doi: 10.1186/1477-7827-11-16
  13. Meirow D, Lewis H, Nugent D, Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclo-phosphamide: Clinical importance and proposed accurate investigative tool. Hum Reprod. 1999;14(7):1903–1907.
  14. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol. 2000;169(1–2):123–131.
  15. Yucebilgin MS, Terek MC, Ozsaran A, et al. Effect of chemotherapy on primordial follicular reserve of rat: An animal model of premature ovarian failure and infertility. Aust N Z J Obstet Gynaecol. 2004;44(1):6–9.
  16. Erken HA, Koç ER, Yazıcı H, et al. Selenium partially prevents cisplatin-induced neurotoxicity: A preliminary study. Neurotoxi-cology. 2014;42:71–75.
  17. Meraner V, Gamper EM, Grahmann A, et al. Monitoring physical and psychosocial symptom trajectories in ovarian cancer pa-tients receiving chemotherapy. BMC Cancer. 2012;12:77. https://doi.org/10.1186/1471-2407-12-77
  18. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378.
  19. Lomeli N, Di K, Czerniawski J, Guzowski JF, Bota DA. Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats. Free Radic Biol Med. 2017;102:274–286.
  20. Coronel MF, Labombarda F, Roig P, Villar MJ, De Nicola AF, González SL. Progesterone prevents nerve injury-induced allo-dynia and spinal NMDA receptor upregulation in rats. Pain Med. 2011;12(8):1249–1261.
  21. Liu A, Margaill I, Zhang S, et al. Progesterone receptors: A key for neuroprotection in experimental stroke. Endocrinology. 2012;153(8):3747–3757.
  22. Graziano V, Check JH, Dietterich C, Choe JK, Yuan W. A comparison of luteal phase support in graduated estradi-ol/progesterone replacement cycles using intramuscular progesterone alone versus combination with vaginal supposito-ries on outcome following frozen embryo transfer. Clin Exp Obstet Gynecol. 2005;32(2):93–94.
  23. Li S, Yixi S, Feng M, Lü P, Huang H, Zhou J. Progesterone inhibits Toll-like receptor 4-mediated innate immune response in macrophages by suppressing NF-KB activation and enhancing SOCS1 expression. Immunol Lett. 2009;125(2):151–155.
  24. He J, Evans CO, Hoffman SW, Oyesiku NM, Stein DG. Progesterone and allopregnanolone reduce inflammatory cytokines af-ter traumatic brain injury. Exp Neurol. 2004;189(2):404–412.
  25. Miller L, Hunt JS. Regulation of TNF alpha production in activated mouse macrophages by progesterone. J Immunol. 1998;160:5098–5104.
  26. Hardy DB, Janowski BA, Corey DR, Mendelson CR. Progesterone receptor plays a major anti-inflammatory role in human my-ometrial cells by antagonism of nuclear factor-kappaB activation of cyclooxygenase 2 expression. Mol Endocrinol. 2006;20(11):2724–2733.
  27. Visser JA, Themmen AP. Anti-Müllerian hormone and folliculogenesis. Mol Cell Endocrinol. 2005;234(1–2):81–86.
  28. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anti-cancer Agents Med Chem. 2007;7(1):3–18.
  29. Devarajan P, Savoca M, Castaneda MP, et al. Cisplatin-induced apoptosis in auditory cells: Role of death receptor and mito-chondrial pathways. Hear Res. 2002;174(1–2):45–54.
  30. Yao XL, Liu J, Lee E, Ling GS, McCabe JT. Progesterone differentially regulates pro- and an-tiapoptotic gene expression in cerebral cortex following traumatic brain injury in rats. J Neu-rotrauma. 2005;22(6):656–668.
© Wroclaw Medical University